Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

Gut

Volumn 63, Issue 1, 2014, Pages 88-95

  Peyrin Biroulet, Laurent ^a   Reinisch, Walter ^b   Colombel, Jean Frederic ^c   Mantzaris, Gerassimos J ^d   Kornbluth, Asher ^c   Diamond, Robert ^e   Rutgeerts, Paul ^f   Tang, Linda K ^e   Cornillie, Freddy J ^g   Sandborn, William J ^h  

^a CHU NANCY BRABOIS   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d EVANGELISMOS HOSPITAL   (Greece)

^e Janssen Biotech Inc   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g Janssen Biologics   (Netherlands)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CDAI SCORE; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ULCER HEALING;

INFLAMMATORY BOWEL DISEASE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLON; COLONOSCOPY; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ILEUM; INDUCTION CHEMOTHERAPY; INTESTINAL MUCOSA; MALE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84888400869     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-304984     Document Type: Article

References (16)

1. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-30. (Pubitemid 34117002)
2. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
3. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
4. Thia K, Faubion WA Jr, Loftus EV Jr, et al. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis 1002;17:105-11.
5. Andre C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981;22:571-4. (Pubitemid 11053344)
6. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. GUT 1994;35:231-35. (Pubitemid 24092870)
7. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-18.
8. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42. (Pubitemid 43261469)
9. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 1383;362:1383-95.
10. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178-81.
11. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83.
12. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11.e2.
13. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-12. (Pubitemid 41271173)
14. Baars JE, Nuij VJ, Oldenburg B, et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 1002;2011:21925.
15. Samuel S, Bruining DH, Loftus EV Jr, et al Endoscopic skipping of the distal terminal ileum in crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol 2012;10:1253-9.
16. Ferrante M, Colombel JF, Sandborn WJ, et al. Evolution of endoscopic activity scores in patients with crohn's disease under azathioprine and/or infliximab: a post-hoc analysis of the sonic data. Gastroenterology 2011;140(Suppl 1):S422.